newsfilter
← Latest News
GlobeNewswire·

ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement

YONKERS, N.Y., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and